Participated · Equity · Jul 2026

DigiSchool develops and operates digital education services and platforms for learners and educational markets. The company intends to expand both organically and through acquisitions to broaden its service offering and market reach. Its platform technology has received targeted public support from Bpifrance, including a €600,000 prêt participatif and a €500,000 zero-interest loan for innovation. DigiSchool has previously benefited from innovation aids and earlier seed-stage participative financing and was formerly associated with Kreactive. The recent €3 million fundraising with Groupe Turenne Capital, Alto Invest and historical investors is intended to finance its external and internal growth initiatives. The company is headquartered in Lyon.

Participated · Series B · Feb 2026

Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on modulating G protein-coupled receptors (GPCRs) to improve patient outcomes in immuno-oncology and inflammation. The company’s lead program is a clinical-stage, Treg-depleting anti-CCR8 antibody that management says offers differentiated competitive features. A second program, currently at the pre-IND stage, is a first-in-class biased antagonist of PAR2 aimed at inflammatory pathways. By advancing these assets, Kainova seeks to build a diversified pipeline of GPCR-targeting therapies that can address multiple high-value indications. The firm operates across North America, France, and Australia, leveraging global clinical infrastructure. Proceeds from its recent Series B financing will be used to move its GPCR programs further into clinical development. No revenue, patient enrollment, or other operating metrics were disclosed, reflecting its pre-commercial status.

Participated · Series A · Jan 2025

Coave Therapeutics is a genetic medicines company based in Paris that develops technologies to improve genetic medicine delivery. Its proprietary ALIGATER™ platform is designed to enhance targeting, specificity, efficacy and manufacturability of genetic medicines. The company is focused on overcoming gene therapy delivery challenges to extra-hepatic tissues and is building a pipeline targeting CNS, neuromuscular and eye diseases. Led by CEO Rodolphe Clerval, Coave positions ALIGATER as a platform with broad clinical applications. The company raised €32M in a Series A to advance the ALIGATER platform. Emmanuelle Coutanceau from Novo Holdings and Jean Francois Morin from Bpifrance will join Coave’s board of directors in connection with the financing. Coave Therapeutics develops targeted genetic medicines using its proprietary ALIGATER™ platform, which chemically modifies AAV capsids or lipid nanoparticles to improve efficacy, safety, and manufacturability. The company’s conjugated vectors (coAAV) enable targeted delivery to the central nervous system and the eye, achieving improved transduction and biodistribution across species at low doses. Its lead disclosed program in the article, CTx-TFEB, is a coAAV-delivered TFEB gene therapy designed to promote autophagy and clear toxic protein aggregates in neurons as a potential pan-ALS treatment. Coave recently received grant funding from the ALS Association to advance CTx-TFEB through preclinical proof-of-concept and aims to establish robust preclinical data to support a clinical transition. The company is headquartered in Paris, France and states its pipeline targets both rare and prevalent neurodegenerative and ocular indications. Coave is backed by unnamed international life sciences investors mentioned in the company description. Coave Therapeutics is a clinical-stage biotech advancing gene therapies for rare ocular and CNS diseases using its AAV-Ligand Conjugate (ALIGATER) platform. Its lead candidate, CTx-PDE6b, is a first-in-class AAV-based gene therapy designed to deliver a full-length functional PDE6b gene for PDE6b-associated retinitis pigmentosa and is currently in a Phase I/II trial. The company has entered a licensing and co-development partnership with Théa Open Innovation to advance CTx-PDE6b through clinical development and commercialization in Europe and adjacent territories. Under the agreement Coave will co-develop the program with Théa and share development costs while retaining commercialization rights outside the partner territories, including the US. Financially, Coave will receive an upfront payment and an equity investment of €10 million and is eligible to receive up to €65 million in development, regulatory and commercial milestone payments, plus double-digit royalties on net sales in licensed territories. Coave is headquartered in Paris and is backed by investors including Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne. Coave Therapeutics, led by CEO Rodolphe Clerval and based in Paris, is advancing targeted gene therapies using its AAV-Ligand Conjugate (ALIGATER) platform to enhance AAV delivery and transduction. The company is progressing a pipeline that includes the lead clinical program CTx-PDE6b, currently in a Phase I/II trial, and preclinical candidates such as CTx-GBA1 (Parkinson’s disease and Gaucher disease) and CTx-ABCA4 (Stargardt’s disease). Coave will use proceeds to push CTx-PDE6b toward pivotal trials, further develop the ALIGATER platform, advance new preclinical coAAV programs in rare CNS and ocular diseases, and seek partnerships to accelerate clinic entry. The company is clinical-stage and focused on producing targeted gene therapy products via proprietary chemical conjugation of AAV vectors. Financially, the company has raised a total of €33.1M following the Series B expansion.

Led · Equity · Feb 2024

Pixee Medical develops augmented- and mixed-reality navigation platforms for orthopedic implant placement, including Knee+ for total knee replacement and Shoulder+ for total shoulder replacement. Its Knee+ system combines augmented-reality glasses and reusable instruments, has CE certification and FDA 510(k) clearance, and has been used in more than 5,000 patient procedures worldwide. Shoulder+ obtained CE mark certification in 2023 and is anticipating FDA approval by the end of the year. The company says clinical studies have validated the precision and effectiveness of its technology and positions its solutions for ambulatory surgery centers. Pixee plans to accelerate U.S. expansion with a subsidiary opening in the first quarter, deploy a new range of augmented reality navigation platforms, open an office in Singapore to expand in Asia, and hire additional talent. The company was founded in 2018 and is advancing next-generation products that incorporate immersive technologies, connectivity, and artificial intelligence. The recent capital raise will support these product and geographic expansion plans.

Participated · Series B · Dec 2023

Antabio is a clinical-stage biopharmaceutical company based in Labège, France, led by CEO and founder Marc Lemonnier. It develops novel and highly differentiated antibacterial treatments addressing CDC/WHO critical priority drug-resistant pathogens, with particular emphasis on life‑threatening respiratory infections and hospital-acquired infections. Its lead program, MEM-ANT3310, is a next‑generation antibacterial combination currently in Phase 1 trials being developed for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). The company’s pipeline also includes ANT3273, an inhalation treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary disease patients, and ANT2681, a metallo beta‑lactamase (MBL) inhibitor intended to be combined with meropenem for MBL-producing CRE, including NDM strains. Antabio plans to use the recent financing to support the clinical development of MEM-ANT3310. Antabio is a private biopharmaceutical company founded in 2009 in Labège, France, focused on developing novel antibacterial resistance-breakers for high unmet medical needs. Its core programs include a metallo ß-lactamase inhibitor to be combined with a carbapenem for nosocomial infections and a first-in-class inhibitor of Pseudomonas virulence (PEi) for chronic respiratory infections. The PEi program is being developed as an inhaled adjunct to standard-of-care antibiotics targeting the LasB elastase to reduce tissue damage, inflammation, and pathogen persistence in cystic fibrosis lungs. The company has received Wellcome Trust Seeding Drug Discovery Awards for two programs, supporting its preclinical efforts. Antabio aims to advance its PEi candidate through non-GLP preclinical studies and toward clinical development as a means to enhance existing antibiotic effectiveness for CF patients. The firm positions its work against the global antimicrobial-resistance challenge and seeks to deliver innovative, life-saving therapeutic options. Antabio SAS is a Labège, France–based biopharmaceutical company led by CEO Marc Lemonnier that develops novel antibacterial resistance‑breakers for high‑unmet‑need drug‑resistant infections. Its lead program is a novel inhibitor of bacterial metallo ß‑lactamases (MBLs) intended to be combined with a carbapenem to treat nosocomial drug‑resistant infections. A second program is a first‑in‑class inhibitor of Pseudomonas virulence to be co‑administered with standard‑of‑care antibiotics for long‑term management of chronic respiratory infections. Another program, the Pseudomonas Elastase Inhibitor (PEI), has received CARB‑X funding. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards. The company expects its lead product to enter the clinic in 2019 with anticipated fast track approval. The new Series A funding will be used to accelerate development of the MBL inhibitor program.